Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ETER100
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
- NCT04523272 ↗
- Unknown
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Standard
We haven't built an HCP commentary report on ETER100 (benmelstobart plus anlotinib in first-line advanced renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ETER100 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Advanced Renal Cancer
- Interventions
- TQB2450; Anlotinib; Sunitinib
- Arms
- TQB2450 + Anlotinib · Experimental
- Sunitinib Malate Capsules · Active comparator
- Enrollment
- 528
- Primary outcomes
- Progression free survival (PFS) evaluated by Independent Review Committee(IRC)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Start
- Aug 25, 2020
- Primary completion
- Jun 2025 (estimated)
- Results posted
- No
- Registry record
- NCT04523272 · updated Oct 15, 2024
Publications
linked from the registry- Li J, Tian H, Xu H, Yan X, Tang B, Li S, Zhou L, Wu X, Chi Z, Cui C, Si L, Guo J, Sheng X. Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study. BMC Med. 2026 Jul 1. doi: 10.1186/s12916-026-05026-0. Online ahead of print. PubMed 42387482
- Zhou A, Shen P, Li J, Qu W, Wang Z, Ren X, Li Y, Jiang S, Li G, Zeng Y, Qin W, Wu J, Chen P, Zhou F, Guo H, Ji Z, Wang Y, He Z, Wu J, Shi B, Liu L, Yao X, Ma L, Liu Z, Gou X, Fu B, Wang S, Jiang K, Chong T, Tu X, Zhang X, Yu D, Rexiati M, Xue X, Fei J, Wan J, Jia L, He Y, Cui T, Yang AQ, Guo J, Sheng X. First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Sep;26(9):1145-1157. doi: 10.1016/S1470-2045(25)00343-2. PubMed 40907513